Canopy Growth Q2 Loss Widens to $0.07, Misses Estimates

What happened

Canopy Growth reported a quarterly loss of $0.07 per share, significantly worse than the Zacks Consensus Estimate of a $0.02 loss and a sharp deterioration from the $0.01 loss in the year-ago quarter. The company also lagged revenue estimates, indicating that top-line growth was weaker than expected despite prior gains in Canadian adult-use and medical segments. The widened loss raises concerns about the sustainability of recent operational improvements, as cost cuts and debt reduction have not yet led to bottom-line stabilization. This result challenges the market's assumption that Canopy is on a clear path to adjusted EBITDA breakeven, and may reflect ongoing price compression, integration costs, or unexpected operating headwinds. The report likely pressures the stock and reinforces the need for a cautious stance until the company demonstrates durable profitability.

Implication

The miss on both EPS and revenue indicates that Canopy's core operations are not yet generating sufficient earnings to offset ongoing costs, undermining the base case of approaching EBITDA breakeven by FY2027. With a loss of $0.07 versus the prior year's $0.01, the company's cost-cutting measures may be losing momentum or being outpaced by revenue weakness and pricing pressure in the competitive Canadian market. The balance sheet remains a relative strength with net cash, but continued losses will erode that buffer and may force more equity issuance, increasing dilution risk for shareholders. The pending MTL Cannabis acquisition may help, but integration risk and the possibility of overpaying in a still-challenged environment add further uncertainty. Until Canopy can string together consistent quarters of narrowing losses or positive cash flow, the stock is likely to remain range-bound with a downward bias, and the attractive entry point may be lower than previously estimated.

Thesis delta

The thesis shifts slightly more cautious: the Q2 loss blew through estimates, showing that cost cuts and Canadian revenue growth have not yet translated into bottom-line improvement. The probability of achieving breakeven adjusted EBITDA by FY2027 decreases, and the risk of further dilution rises. Consequently, the attractive entry point may need to be lowered, or the re-assessment window extended, and the rating remains WAIT.